ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
128.150,71
-0,10%
S&P 500
5.303,27
0,12%
US Dollar vs BRL
5,10192
-0,05%
Bitcoin
66.296,92
-0,96%
Brent Oil
83,76
0,00%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. PepGen Inc (PEPG)

  7. PepGen Inc (PEPG) Notícias

PEPG

PepGen (PEPG)

PepGen Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:PEPG
DataHoraFonteTítuloCódigoCompanhia
17/05/202421:51Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PEPGPepGen Inc
17/05/202417:33Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:PEPGPepGen Inc
14/05/202417:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PEPGPepGen Inc
14/05/202417:02GlobeNewswire Inc.PepGen Reports First Quarter 2024 Financial Results and Recent Corporate HighlightsNASDAQ:PEPGPepGen Inc
14/05/202417:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PEPGPepGen Inc
13/03/202417:05GlobeNewswire Inc.PepGen to Participate in Upcoming Investor ConferencesNASDAQ:PEPGPepGen Inc
13/03/202408:00GlobeNewswire Inc.PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular DystrophyNASDAQ:PEPGPepGen Inc
06/03/202418:23Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:PEPGPepGen Inc
06/03/202418:01GlobeNewswire Inc.PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate DevelopmentsNASDAQ:PEPGPepGen Inc
04/03/202409:00GlobeNewswire Inc.PepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular DystrophyNASDAQ:PEPGPepGen Inc
20/02/202410:00GlobeNewswire Inc.PepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1NASDAQ:PEPGPepGen Inc
07/02/202418:55Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:PEPGPepGen Inc
07/02/202409:30GlobeNewswire Inc.PepGen Announces Pricing of $80.1 Million Underwritten Offering of Common StockNASDAQ:PEPGPepGen Inc
17/01/202409:00GlobeNewswire Inc.Mary Beth DeLena Joins PepGen as General Counsel and SecretaryNASDAQ:PEPGPepGen Inc
08/01/202409:00GlobeNewswire Inc.PepGen Announces First Patient Dosed in CONNECT1-EDO51 Phase 2 Clinical Trial of PGN-EDO51 for Duchenne Muscular Dystrophy Patients Amenable to Exon 51 SkippingNASDAQ:PEPGPepGen Inc
18/12/202310:00GlobeNewswire Inc.PepGen Announces First Patient Dosed in Phase 1 FREEDOM-DM1 Clinical Trial of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)NASDAQ:PEPGPepGen Inc
15/11/202310:00GlobeNewswire Inc.PepGen Announces Appointment of Howard Mayer, M.D. to Board of DirectorsNASDAQ:PEPGPepGen Inc
08/11/202310:00GlobeNewswire Inc.PepGen Reports Third Quarter 2023 Financial Results and Recent Corporate DevelopmentsNASDAQ:PEPGPepGen Inc
12/10/202308:52Dow Jones NewsFDA Lifts Hold on PepGen's New Drug Application for Dystrophy TreatmentNASDAQ:PEPGPepGen Inc
12/10/202308:00GlobeNewswire Inc.PepGen Inc. Announces FDA has Lifted the Clinical Hold on its Investigational New Drug Application for FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)NASDAQ:PEPGPepGen Inc
27/09/202317:16GlobeNewswire Inc.PepGen Announces Upcoming Presentations at the 28th Annual Congress of the World Muscle Society and the World Congress of NeurologyNASDAQ:PEPGPepGen Inc
06/09/202317:05GlobeNewswire Inc.PepGen Inc. Announces Clearance of CTA by Health Canada to Begin the FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 in Patients with Myotonic Dystrophy Type 1NASDAQ:PEPGPepGen Inc
06/09/202309:00GlobeNewswire Inc.PepGen Inc. Presents PGN-EDODM1 Preclinical Data Supporting the Company’s Enhanced Delivery Oligonucleotide Platform and PGN-EDODM1 Program at Two Medical ConferencesNASDAQ:PEPGPepGen Inc
01/09/202309:00GlobeNewswire Inc.PepGen Announces Presentations at the 2023 Myotonic Dystrophy Foundation Annual Conference, Ottawa Neuromuscular Disease Meeting, and H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:PEPGPepGen Inc
08/08/202309:15GlobeNewswire Inc.PepGen Reports Second Quarter 2023 Financial Results and Recent Corporate DevelopmentsNASDAQ:PEPGPepGen Inc
26/06/202317:17Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:PEPGPepGen Inc
22/06/202317:06Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:PEPGPepGen Inc
13/06/202318:07Dow Jones NewsPepGen Withdraws Guidance on Launch of Study for Muscle Disease TreatmentNASDAQ:PEPGPepGen Inc
13/06/202317:05GlobeNewswire Inc.PepGen Inc. Provides Update on Planned Initiation of Phase 1 Study of PGN-EDODM1 in Myotonic Dystrophy Type 1NASDAQ:PEPGPepGen Inc
02/06/202317:12Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3)NASDAQ:PEPGPepGen Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:PEPG

Seu Histórico Recente

COIN
DACKRW
Davinci coin
EU
CMO
Caisse Regionale de Cred...
EU
KQ77B
KQ77B
ASX
EQH
COIN
TRIASBTC
Trias Token
NASDAQ
TKKSW
TKK Symphony Acquisition
BINA
CELOBTC
Celo
COIN
LUCHOWUST
LunaChow
NASDAQ
AAYEIXX
Barclays Bank Plc Capped...
NASDAQ
AAXOZXX
Goldman Sachs Bank Usa P...
BOV
PETRL281
PETRL281 Ex:25,38
BIT
S27006
Societe Generale Effekten
BTHB
STEEMKRW
Steem
BOV
PETRS235
PETRS235 Ex:20,62
NYSE
TRNO
Terreno Realty
BIT
S25046
SG ISSUER
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados